Published in J Biol Chem on May 24, 2004
Diversifying carotenoid biosynthetic pathways by directed evolution. Microbiol Mol Biol Rev (2005) 2.28
Historical contingency and its biophysical basis in glucocorticoid receptor evolution. Nature (2014) 1.08
Directed evolution of specific receptor-ligand pairs for use in the creation of gene switches. Proc Natl Acad Sci U S A (2005) 1.08
Extending Iterative Protein Redesign and Optimization (IPRO) in protein library design for ligand specificity. Biophys J (2007) 0.94
Directed evolution of homing endonuclease I-SceI with altered sequence specificity. Protein Eng Des Sel (2009) 0.87
Synthetic biology tools for programming gene expression without nutritional perturbations in Saccharomyces cerevisiae. Nucleic Acids Res (2014) 0.83
Discovery and characterization of a new cell-penetrating protein. ACS Chem Biol (2013) 0.77
Elucidating residue roles in engineered variants of AraC regulatory protein. Protein Sci (2010) 0.77
A new fluorescence complementation biosensor for detection of estrogenic compounds. Biotechnol Bioeng (2011) 0.76
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nat Genet (2017) 0.75
Topology characterization of a benzodiazepine-binding beta-rich domain of the GABAA receptor alpha1 subunit. Protein Sci (2005) 0.75
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology (2003) 4.96
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell (2011) 4.04
DNA assembler, an in vivo genetic method for rapid construction of biochemical pathways. Nucleic Acids Res (2008) 3.66
Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res (2004) 3.22
Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology (2006) 2.49
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol (2008) 2.44
Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol (2005) 2.30
Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol (2003) 2.17
International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev (2006) 2.15
Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology (2004) 2.10
Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol (2008) 2.09
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol Biosyst (2012) 2.01
Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. J Biol Chem (2006) 1.91
Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest (2010) 1.90
Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol (2002) 1.83
Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol (2010) 1.75
Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology (2002) 1.74
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
Antagonists selective for estrogen receptor alpha. Endocrinology (2002) 1.70
Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol (2008) 1.70
Localization of androgen and estrogen receptors in adult male mouse reproductive tract. J Androl (2002) 1.69
Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem (2004) 1.67
Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology (2003) 1.66
Yeast surface display of trifunctional minicellulosomes for simultaneous saccharification and fermentation of cellulose to ethanol. Appl Environ Microbiol (2009) 1.55
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res (2008) 1.55
Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol (2007) 1.55
Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Mol Endocrinol (2002) 1.53
New insight into the mechanism of methyl transfer during the biosynthesis of fosfomycin. Chem Commun (Camb) (2006) 1.53
Biomedicine. Defining the "S" in SERMs. Science (2002) 1.52
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52
Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J Med Chem (2004) 1.50
Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster. Chem Biol (2006) 1.47
Adsorption of ionizable organic contaminants on multi-walled carbon nanotubes with different oxygen contents. J Hazard Mater (2010) 1.45
Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J Med Chem (2004) 1.43
Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol (2006) 1.43
Cloning, expression, and biochemical characterization of Streptomyces rubellomurinus genes required for biosynthesis of antimalarial compound FR900098. Chem Biol (2008) 1.41
Customized optimization of metabolic pathways by combinatorial transcriptional engineering. Nucleic Acids Res (2012) 1.41
A repressive role for prohibitin in estrogen signaling. Mol Endocrinol (2007) 1.40
In vitro reconstitution and crystal structure of p-aminobenzoate N-oxygenase (AurF) involved in aureothin biosynthesis. Proc Natl Acad Sci U S A (2008) 1.39
Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol Cell Biol (2010) 1.38
Estrogen receptor β ligands: recent advances and biomedical applications. Med Res Rev (2011) 1.38
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res (2005) 1.37
Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab (2004) 1.37
Recent developments in pyridine nucleotide regeneration. Curr Opin Biotechnol (2003) 1.36
Alteration of large-scale chromatin structure by estrogen receptor. Mol Cell Biol (2002) 1.36
Genetic deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen in target tissues in vivo. Mol Cell Biol (2005) 1.36
Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol (2009) 1.34
A highly sensitive selection method for directed evolution of homing endonucleases. Nucleic Acids Res (2005) 1.34
Elemental isomerism: a boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. Chem Biol (2007) 1.31
Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proc Natl Acad Sci U S A (2005) 1.30
Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnol Bioeng (2013) 1.28
Extranuclear estrogen receptor-alpha stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc Natl Acad Sci U S A (2010) 1.28
Improving cellular malonyl-CoA level in Escherichia coli via metabolic engineering. Metab Eng (2009) 1.26
Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol (2010) 1.25
Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol (2009) 1.25
Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol Cell (2004) 1.24
Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. Mol Cell Biol (2009) 1.22
Amphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid receptor coactivator interaction. ACS Chem Biol (2008) 1.21
Indazole estrogens: highly selective ligands for the estrogen receptor beta. J Med Chem (2005) 1.21
Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci U S A (2013) 1.21
Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng (2013) 1.19
Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem (2008) 1.19
The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res (2005) 1.19
Discovery and characterization of novel d-xylose-specific transporters from Neurospora crassa and Pichia stipitis. Mol Biosyst (2010) 1.19
Rapid characterization and engineering of natural product biosynthetic pathways via DNA assembler. Mol Biosyst (2011) 1.18
Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. Mol Endocrinol (2005) 1.17
Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland. Proc Natl Acad Sci U S A (2006) 1.17
Biosynthesis of 2-hydroxyethylphosphonate, an unexpected intermediate common to multiple phosphonate biosynthetic pathways. J Biol Chem (2008) 1.17
Hormone-PAMAM dendrimer conjugates: polymer dynamics and tether structure affect ligand access to receptors. Angew Chem Int Ed Engl (2006) 1.16
Directed evolution of enzymes and biosynthetic pathways. Curr Opin Microbiol (2006) 1.16
Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities. J Biol Chem (2011) 1.15
Reconstitution and characterization of aminopyrrolnitrin oxygenase, a Rieske N-oxygenase that catalyzes unusual arylamine oxidation. J Biol Chem (2005) 1.15
A new class of arylamine oxygenases: evidence that p-aminobenzoate N-oxygenase (AurF) is a di-iron enzyme and further mechanistic studies. Chembiochem (2006) 1.15
Relaxing the nicotinamide cofactor specificity of phosphite dehydrogenase by rational design. Biochemistry (2003) 1.13
Engineering microbial factories for synthesis of value-added products. J Ind Microbiol Biotechnol (2011) 1.13
Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem Biol (2009) 1.13
The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells. J Neurochem (2008) 1.13
Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97). J Biol Chem (2002) 1.12